Share

    


Home / Search Results

Search Results

Search Publications

Search Again?

Filter By Content Type

Filter By Topic

Adithya Chennamadhavuni, MD University of Iowa Hospitals and Clinics View Poster
Main finding goes here, translated into plain English. Emphasize the important words. SampleID Age Sex Extent of Surgery ECOG at Tx Start Survival Time (mo) MGMT (PCR) MGMT Array Testing IDH Mutation Array Testing BDG2 62 F Gross total resection 1 6.63 Unknown Unmethylated Wild-type BDG5 65 F Gross total resection 1 9.63 Unknown Unmethylated Unknown BDG7 38 F Gross …
Justin Chau, MD University of Iowa Hospitals and Clinics View Poster
Josiah An, MD, MS Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa View Poster
Slide 1 Improving Medication Reconciliation in Ambulatory Oncology Patients Susan Slycord, DO and Isaac Chambers, MD University of Iowa Hospitals & Clinics, Holden Comprehensive Cancer Center Introduction Interventions Conclusions MeasuresResults Medication discrepancies are common and can lead to adverse drug events (ADEs). • ADEs lead to prolonged hospitalizations …
PowerPoint Presentation BACKGROUND • Penile cancer is a relatively rare tumor in developed nations. • HPV is associated with 30 - 50% of penile cancers, with some studies showing improved outcomes in these patients. • In this study, we have evaluated the effect of HPV infection on the outcomes of penile cancer utilizing a contemporary national cancer database (NCDB). …
PowerPoint Presentation Event-Free Survival at 24 Months Following Autologous Stem Cell Transplant in Diffuse Large B-Cell Lymphoma Seth M Maliske, MD1, Matthew J. Maurer, MS2, Carrie A. Thompson, MD3, Luis Porrata, MD3, Ivana Micallef, MD3, Rebecca L. King, MD4, Sergei Syrbu, MD, PhD5, Brian K. Link, MD1, Margarida Magalhaes Silverman, MD1, Yogesh Jethava, MBBS, MD1, David J …
PowerPoint Presentation Introduction Methods and Materials • Risk factors for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) in patients with multiple myeloma (MM) are not well understood. • The excess risk of AML/MDS in Lenalidomide treated patients has been most prominent in patients that also receive alkylating agents. • Delayed autologous transplant found …
This blog is the third of an eight-post ACCCBuzz series highlighting the achievements of the 2020 ACCC Innovator Award Winners. You can learn more about the innovations being recognized this year and the people who pioneered them by joining us at the upcoming ACCC 37th [Virtual] National Oncology Conference, September 14-18. Patient health literacy is an essential—but often lacking—aspect of quality …
Slide 1 COVID-19-associated coagulopathy: Safety and efficacy of prophylactic anticoagulation therapy in hospitalized adults with COVID-19 Isaac Chambers, MD University of Iowa Hospitals & Clinics, Holden Comprehensive Cancer Center Background: • Patients hospitalized with COVID-19 have an elevated risk of thrombosis • Despite use of standard prophylactic …
PowerPoint Presentation Survival Outcomes of Non-metastatic, Non-clear cell Renal Cell Carcinoma (non-ccRCC) after Surgery Josiah An1, Adithya Chennamadhavuni1, Sarah L Mott1, Rohan Garje1 1Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA Introduction Materials and Methods Results Conclusions ▪ Collecting duct and …
“I don’t know a single cancer patient who is not anxious,” says Jenn Paxton, LCSW, OSW-C, a social worker at Texas Oncology in South Dallas. Paxton, who meets with cancer patients from the recently diagnosed to those dealing with end-of-life issues, says accurate, empathetic communication that meets patients where they are on their cancer journeys is essential to providing quality care. Key to doing …
keytruda_pi.pdf HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use KEYTRUDA safely and effectively. See full prescribing information for KEYTRUDA. KEYTRUDA® (pembrolizumab) injection, for intravenous use Initial U.S. Approval: 2014 --------------------------- RECENT MAJOR CHANGES --------------------------- Indications …
1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PHESGO safely and effectively. See full prescribing information for PHESGO. PHESGO (pertuzumab, trastuzumab, and hyaluronidase-zzxf) injection, for subcutaneous use Initial U.S. Approval: 2020 WARNING: CARDIOMYOPATHY, EMBRYO-FETAL TOXICITY, and …
Indications & Important Safety Information Early Breast Cancer PHESGO™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is indicated for use in combination with chemotherapy for • the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node-positive) as part of a complete treatment regimen …
Dear Healthcare Professional, We are writing to inform you that on June 29, 2020, the Food and Drug Administration (FDA) approved PHESGO™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf) injection, for subcutaneous use. PHESGO is a fixed-dose combination of pertuzumab and trastuzumab, HER2/neu receptor antagonists, and hyaluronidase, an endoglycosidase.1 Indications Early Breast Cancer …
This blog is the second of an eight-part ACCCBuzz series highlighting the achievements of the 2020 ACCC Innovator Award Winners. You can learn more about the innovations being recognized this year and the people who pioneered them by joining us at the upcoming ACCC 37th [Virtual] National Oncology Conference, September 14-18. In 2016, Vijay Rao, MD, PhD, was working as a cardiologist at Franciscan …
This blog is the second of an eight-part ACCCBuzz series highlighting the achievements of the 2020 ACCC Innovator Award Winners. You can learn more about the innovations being recognized this year and the people who pioneered them by joining us at the upcoming virtual ACCC 37th National Oncology Conference, September 14-18. In 2016, Vijay Rao, MD, PhD, was working as a cardiologist at Franci
Laura Holmes Haddad shares how her battle with breast cancer changed her perception of the resources available to younger adults with cancer, and what cancer programs can do to meet their needs.
July 10, 2020
Join Charles Saunders, MD, Chief Executive Officer, and Jennifer Webster, MS, Vice President of Analytics, IntegraConnect, as they present an overview of the current landscape of patient levels and services at cancer programs. (July 10, 2020)